Mary-Ellen Taplin
Dana-Farber Cancer Institute · University of Massachusetts, Worcester
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
20
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
NIH RePORTER
Trial papers
77
PubMed author-name match
Trials
Studies that name Mary-Ellen Taplin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:47 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03887091 · Personal Web Page In Clinical Trial Participant EducationDana-Farber Cancer Institute · completed · Prostate Cancer, Kidney Cancer, Genitourinary Cancer · principal investigator
- Ph2NCT02903368 · Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing ProstatectomyDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
- Ph2NCT02268175 · Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateDana-Farber Cancer Institute · completed · Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer · principal investigator
- Ph2NCT02025010 · Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate CancerDana-Farber Cancer Institute · completed · Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT01942837 · Study of Enzalutamide in Patients With Castration-resistant Prostate CancerDana-Farber Cancer Institute · completed · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT01709734 · A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate CancerLTN PHARMACEUTICALS, INC. · terminated · Prostate Cancer
- Ph2NCT01393730 · Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerMary-Ellen Taplin, MD · completed · Prostate Cancer · principal investigator
- N/ANCT01275651 · Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With KetoconazoleAlliance for Clinical Trials in Oncology · withdrawn · Prostate Cancer · study chair
- N/ANCT00898833 · Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583Alliance for Clinical Trials in Oncology · terminated · Prostate Cancer
- Ph2NCT00776594 · Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local TherapyDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
- Ph2NCT00658697 · Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate CancerDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
- Ph2NCT00630344 · RAD001 and Bicalutamide for Androgen Independent Prostate CancerDana-Farber Cancer Institute · completed · Prostate Cancer · study chair
- Ph1/Ph2NCT00459186 · The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate CancerDana-Farber Cancer Institute · completed · Metastatic, Androgen Independent Prostate Cancer, Prostate Cancer
- Ph2NCT00321646 · Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical ProstatectomyMary-Ellen Taplin, MD · completed · Prostate Cancer, Adenocarcinoma of the Prostate · principal investigator
- Ph2NCT00165399 · Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local TreatmentDana-Farber Cancer Institute · completed · Adenocarcinoma of the Prostate, Prostate Cancer · principal investigator
- N/ANCT00165386 · MRI-guided Bone Marrow Biopsies of Prostate Cancer PatientsDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
- Ph2NCT00140478 · Mifepristone (RU-486) in Androgen Independent Prostate CancerDana-Farber Cancer Institute · completed · Prostate Cancer, Adenocarcinoma of Prostate · principal investigator
- Ph2NCT00134706 · A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate CancerDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
- N/ANCT00002924 · Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone TherapyAlliance for Clinical Trials in Oncology · completed · Prostate Cancer · study chair
- Ph2NCT00005096 · Docetaxel in Treating Patients With Stage II or Stage III Prostate CancerDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Efficacy and Mechanisms of Resistance to Neoadjuvant Intensive Androgen Signaling InhibitionP50CA272390 · NCI · DANA-FARBER CANCER INST · fiscal years 2023 to 2025 · $448,227 awarded in 2025Same name and institution; not confirmed by an ID
- CANCER AND LEUKEMIA GROUP BU10CA077225 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · fiscal years 2000 to 2002 · $106,578 awarded in 2002Same name and institution; not confirmed by an ID
- ANDROGEN RECEPTOR ANALYSIS IN REFRACTORY PROSTATE CANCERU10CA078967 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · fiscal years 1998 to 1999 · $148,354 awarded in 1999Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- U10CA031946RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00002924
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT00005096
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:47 UTC. The ranking covers the 200 most relevant of 77 PubMed records, and a shared surname and initials can bring in a namesake. All 77 on PubMed
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med · 20123,750 citationsRCR 102.0
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med · 20043,025 citationsRCR 65.3
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med · 20142,392 citationsRCR 70.7
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- 1,126 citationsRCR 35.2
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.Lancet · 2010875 citationsRCR 21.9
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.J Clin Oncol · 2010342 citationsRCR 8.9
- Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.J Clin Oncol · 2003288 citationsRCR 5.7
- 282 citationsRCR 6.4
- 248 citationsRCR 6.8